Skip to main content

You’re reading the web edition of STAT Health Tech, our guide to how technology is transforming the life sciences. Sign up to receive this newsletter delivered to your inbox every Tuesday and Thursday.

Over the past year, Katie has entered the science and business of continuous glucose monitors. For a complete overview of the future of devices, not only for diabetic patients, but for the general public, pick up a copy of our new STAT report.

Biosensors at three-letter conferences


Speaking of CGM, device maker Dexcom presentation to the virtual whole of this week JP Morgan Healthcare Conference finally showed forward movement on its next-generation continuous glucose monitor, the G7. The company filed with the FDA in late 2021 and shared data from its submission to JPM, including results showing the device meets standards to feed its data into automated insulin pumps. “Our current systems have been designed to easily connect with the automated insulin delivery developments that will emerge over the next several years,” said CEO Kevin Sayer. “I would even go so far as to say that data sharing is perhaps one of the most important innovations this company has made in its history.”

News arrives as Dexcom’s main competitor Abbott made a bold announcement last week at CES that the company will launch a new line of consumer-grade disposable biosensors dubbed Jargon. The first device will measure ketones, targeting fans of the fad keto diet, although observers suggest such detection could be a nice addition for patients who diligently track their numbers to avoid diabetic ketoacidosis. The company is also planning consumer glucose and lactate biosensors to help people optimize nutrition and exercise. As blood sugar monitoring companies aim to acquire a growing user base, Dexcom may have to decide whether to focus on making the best possible product for people with diabetes or on the best possible product for people with diabetes. largest possible market by providing a new generation of user sensors.


In other news at JPM …

  • Teladoc slightly increased revenue projections for fiscal 2021 to $ 2.03 billion, as CEO Jason gorevic doubled the company’s vision for “comprehensive human care”: virtually addressing the mental, physical, chronic and complex needs of patients and connecting them to physical services when needed.
  • frames with Oak Street Health, a virtual and in-person primary care provider for Medicare patients, said it would pave the way for its expansion plans in 2022, adding 70 new health centers. This would give the company a total of 200 clinics nationwide, in addition to a virtual specialty consulting business that it added through the acquisition of Rubicon®. However, the company is also facing headwinds, including a Justice Department investigation into whether it violated the false claims law related to third-party marketing activities.

Coming today to JPM: publisher of value-driven healthcare software Alédade is expected to announce Tuesday its first acquisition at JPM: Iris Healthcare, which sells support for advanced care planning. Aledade was founded by Farzad Mostashari, the top federal health information technology official under President Barack Obama.

The 23andMe Cancer Play

Last week, 23 and me has begun clinical trials of its first wholly owned cancer immunotherapy drug – a milestone for a company trying to expand into drug development from its roots in consumer genetic testing. It is the second anti-cancer drug the company has advanced in human trials, following immunotherapy developed in partnership with GSK. But as 23andMe dives headlong into pharmaceutical deadlines, there’s still room for more on the consumer side: On Monday, the company announced it had received FDA authorization of his third DTP genetic test, for an inherited marker of prostate cancer. This is the longest of the long pieces, but it will be interesting to see if the company can successfully sell prevention and treatment at the same time, for the same disease.

A small step for data standards …

The Office of the National Coordinator published a technical specification for recording patient addresses in digital records. It sounds like a small thing, but the formatting differences often result in an inability to accurately identify patients and track their records. The new specification, called Project [email protected], will help advance interoperability between healthcare IT systems and help organizations link patient records held by different providers and insurers, provided they all adopt the standards. Speaking of standards, ONC has also released its revised interoperability guide.

Mergers and acquisitions intensify

  • Withings is acquiring Impeto Medical, the maker of technology to detect chemotherapy-related small-fiber neuropathy as well as diseases such as diabetes and Parkinson’s disease. Withings plans to integrate the technology into its home body analysis device to detect common conditions.
  • R1 RCM, a maker of technology to improve supplier financial performance, acquires Atlanta-based revenue cycle company Cloudy in a transaction all stock. The deal values ​​Cloudmed at $ 4.1 billion.
  • The voice assistant company Speak2Family acquires a rival Healthy mind for an undisclosed sum. Both companies use voice assistants to help the elderly with their daily tasks.
  • LG equips all its 2021 and 2022 smart TVs with a telehealth application from the platform dedicated to seniors Independence. The app will allow clients to schedule and make telehealth appointments through their televisions.
  • Home care business Medically at home raised $ 110 million in new funding from Baxter International, Global medical response and Cardinal Health. Its existing supplier partners, Mayo Clinic and Kaiser Permanente, also injected more money.
  • Little otter, a provider of digital mental health services for children and families, raised $ 22 million in a Series A run by CRV. The company will use the funding to expand beyond existing availability in California, Colorado, North Carolina and Florida.

What we read